NCT04549064

Biomarkers of Pancreatic Cancer and New Way to Detection

Identification of AREG for the Detection of Pancreatic Cancer By Biosensor

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 600 (estimated)
• Sponsor: First Affiliated Hospital Xi'an Jiaotong University · Academic / Other
• Sex: All
• Age: 20 Years – 90 Years
• Healthy volunteers: Accepted

Summary

Amphoteric regulatory protein (AREG), a member of epidermal growth factor (EGF) family, is expressed in many tumors.Our study confirmed that the expression of AREG in the serum of patients with pancreatic cancer is significantly higher than that of patients with benign pancreatic diseases and healthy people, which is expected to become a new early serum marker of pancreatic cancer. The serum concentration of AREG was detected by traditional ELISA and compared with CA-199, which was a conventional tumor marker of pancreatic cancer. Next, we compare the advantages of using sensor to detect AREG compared with ELISA.

Detailed description

Serum was collected ： pancreatic cancer : healthy control =200:200 Clinical data were collected: age, gender, diagnosis, cancer stage, CA199 level at initial diagnosis, histopathological type, etc. The informed consent of the subjects was obtained before the study, and all experimental procedures were approved by ethics. Draw a summary table of patient characteristics. The level of AREG was detected by ELISA kit and compared with CA199. Fabrication of a new electrochemical biosensor. Characterization of sensor performance.

Conditions

• Pancreatic Cancer

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	diagnosis of pancreatic cancer	Diagnosis of pancreatic cancer based on the concentration of serum biomarkers

Timeline

• Start date: 2020-09-01
• Primary completion: 2021-12-01
• Completion: 2021-12-30
• First posted: 2020-09-16
• Last updated: 2021-08-23

Locations

1 site across 1 country: China